Scandinavian Real Heart AB (publ) announces that the company’s half-year report for the period January – June 2026 will be published on August 26, 2026, instead of August 28, 2026, as previously communicated in the company’s financial calendar.
The reason for the change is that work on the half-year report was completed earlier than planned.
The company’s financial calendar on its website will be updated in conjunction with the publication of this press release.
Västerås, Sweden, June 16, 2026 – Scandinavian Real Heart AB (publ) today released the recording of the Annual General Meeting held at the Company’s new premises in Västerås on May 28, 2026.
In connection with the Company’s Annual General Meeting, CEO Ina Laura Perkins gave an updated presentation on the current status of the Company’s total artificial heart, Realheart® TAH, to the shareholders in attendance. This time, the entire management team, and the Board of Directors were also present.
The recording, which is just over 27 minutes long, is primarily in Swedish, but also includes segments in English where the management and board members introduce themselves.
Link to the recording: https://youtu.be/sQDKo1fs824
For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se
About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se
On 28 May 2026, Scandinavian Real Heart AB (the "Company") held its Annual General Meeting (AGM) at which the following resolutions were adopted.
Adoption of the income statement and balance sheet, disposition of earnings and discharge from liability.
The AGM resolved to adopt the presented income statement and balance sheet for the financial year 2025. Furthermore, the AGM resolved that no dividend will be paid for the financial year 2025 and that the retained earninngs shall be carried forward. The AGM discharged the members of the Board of Directors and the CEO who served during the financial year 2025 from liability towards the Company.
Determination of fees to the Board of Directors and auditor
The AGM resolved that remuneration to the Chairman of the Board of Directors shall be paid in the amount of SEK 160,000 and in the amount of SEK 77,500 to each of the other Board members who are not employed by the Company. It was resolved that fees to the auditor shall be paid in accordance with approved invoices.
Election of Board of Directors and auditor
It was resolved that the Board of Directors shall consist of six members and no deputies and that the appointed auditor shall be a registered auditing firm. Furthermore, for the period until the end of the next Annual General Meeting, it was resolved to re-elect Azad Najar, Oliver Voigt, Giovanni Lauricella, Stuart McConchie, Oskar Mellgren and Mia Tomczak as members of the Board of Directors. Oskar Mellgren was elected as Chairman of the Board.
The auditing firm Grant Thornton Sweden AB was re-elected as auditor for the period until the 2027 Annual General Meeting. The company has been informed that Joakim Söderin will be appointed auditor in charge.
Nomination Committee
The AGM resolved that the Nomination Committee for the 2027 Annual General Meeting shall consist of Claes Mellgren.
Authorization for the Board of Directors to issue shares
The AGM resolved to authorize the Board of Directors to, within the framework of the current Articles of Association, with or without deviation from the shareholders' preferential rights, on one or more occasions during the period until the next Annual General Meeting, resolve to increase the Company's share capital through a new issue of shares in the Company. The purpose of the authorization is to increase the company's financial flexibility.
Complete resolutions as set out above are available on the Company's website, www.realheart.se
Scandinavian Real Heart AB (”Bolaget”) har den 28 maj 2026 hållit årsstämma där i huvudsak följande beslut fattades.
Fastställande av resultat- och balansräkning, resultatdisposition och ansvarsfrihet.
Stämman beslutade att fastställa den framlagda resultat- och balansräkningen för räkenskapsåret 2025. Vidare beslutade stämman att ingen utdelning lämnas för räkenskapsåret 2025 och att resultatet ska balanseras i ny räkning. Stämman beviljade styrelsens ledamöter och den verkställande direktören som varit verksam under räkenskapsåret 2025 ansvarsfrihet gentemot Bolaget.
Fastställande av arvoden åt styrelse och revisor
Stämman beslutade att styrelsearvode ska utgå till styrelseordförande med 160 000 kronor och med 77 500 kronor till var och en av de övriga ledamöter vilka ej är anställda av Bolaget. Arvode till revisorn beslutades utgå enligt godkänd räkning.
Val av styrelse och revisor
Det beslutates att styrelsen skall bestå av sex ledamöter och inga suppleanter samt att utsedd revisor skall vara ett registrerat revisionsbolag. Vidare beslutades, för tiden intill slutet av nästa årsstämma, omval av Azad Najar, Oliver Voigt, Giovanni Lauricella, Stuart McConchie, Oskar Mellgren och Mia Tomczak som styrelseledamöter. Oskar Mellgren valdes som styrelseordförande.
Till revisor omvaldes revisionsbolaget Grant Thornton Sweden AB för tiden intill årsstämman 2027. Bolaget har blivit informerad om att Joakim Söderin kommer att utses till huvudansvarig revisor.
Valberedning
Stämman beslutade att valberedningen inför årsstämman 2027 ska bestå av Claes Mellgren.
Bemyndigande för styrelsen att emittera aktier
Stämman beslutade om bemyndigande för styrelsen att inom ramen för gällande bolagsordning, med eller utan avvikelse från aktieägarnas företrädesrätt, vid ett eller flera tillfällen under tiden fram till nästa årsstämma fatta beslut om ökning av Bolagets aktiekapital genom nyemission av aktier i Bolaget. Syftet med bemyndigandet är att öka bolagets finansiella flexibilitet.
Fullständiga beslut enligt ovan finns tillgängliga på Bolagets webbplats, www.realheart.se
Västerås, Sweden, May 28, 2026 – Scandinavian Real Heart AB (publ) announces today that CEO Ina Laura Perkins will present the company’s current progress, and future plans for Realheart® TAH at the Annual General Meeting on Thursday, May 28, 2026. The meeting will be held at the company’s new premises on Hydrovägen in Västerås.
During the presentation, Ina Laura Perkins will provide an update on the company’s progress in the field of artificial hearts and the activities underway in preparation for upcoming regulatory and clinical steps.
The recent achievements to be presented are as follows:
“We look forward to welcoming our shareholders to our new offices in Västerås and, at the same time, providing an update on the significant progress being made in the development of Realheart® TAH. We remain focused on achieving the next key milestones in the company’s development,” says Ina Laura Perkins, CEO of Realheart.
A recording of the presentation will be available shortly, and we will announce when it is ready.
Västerås, Sweden, June 28, 2026 – Scandinavian Real Heart AB (publ) today announced that IP Australia, the Australian intellectual property rights agency, has granted Realheart a patent covering central aspects of the Realheart® TAH technology. The granted claims include the design and operation of the total artificial heart, as well as the integrated feedback mechanism that regulates the device's cardiac output. The patent remains in force in Australia until 2041.
Realheart is developing Realheart® TAH, the first total artificial heart designed to replicate the four-chamber structure and pumping cycle of the native human heart. The granted patent covers sensor technology that provides accurate pressure measurements, enabling real-time monitoring and automated control of artificial hearts and circulatory support systems, including Realheart® TAH.
Realheart® TAH is intended as a treatment alternative for patients awaiting a heart transplant, with the potential to improve quality of life during that period. The structural design of Realheart® TAH aims to reduce risk factors commonly associated with currently available artificial heart devices, such as stroke, internal bleeding, and anaemia.
Region: Australia
Patent number: 2021236921
Expiration date: March, 2041
Västerås, Sweden, June 28, 2026 – Scandinavian Real Heart AB (publ) announces today that the company has been granted a patent approval in China. The patent covers a control method and system configuration for artificial heart products, such as Realheart® TAH, featuring integrated feedback mechanisms for real-time regulation of cardiac output. The approval grants patent protection in China until March 2041.
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The patent (ZL2021800364627) covers a control method and system configuration for an artificial heart, featuring integrated feedback mechanisms for real-time regulation of cardiac output. In detail, the system is designed to ensure precise and safe control of pump performance in medical environments.
The method supports continuous monitoring and adaptive adjustment of key parameters, including pressure, flow, and pump speed, enabling automated control of artificial hearts and circulatory support systems such as Realheart® TAH. This is intended to support hemodynamic stability, with the potential to contribute to improved treatment outcomes. The method and associated configuration are designed for integration into Realheart’s existing and future pump devices, and are also compatible with third-party total artificial heart and circulatory support systems.
Region: Mainland China
Patent number: ZL 2021800364627
Expiration date: March 2041
Aktieägarna i Scandinavian Real Heart AB, org.nr. 556729–5588 (”Bolaget”), kallas härmed till årsstämma den 28 maj kl. 17.00 på Scandinavian Real Hearts huvudkontor, Hydrovägen 4, 721 36 Västerås. Inregistrering till stämman börjar kl. 16.30.
Rätt att delta vid stämman m.m.
Aktieägare som önskar delta vid stämman ska
• dels vara införd i den av Euroclear Sweden AB förda aktieboken senast den 20 maj 2026, och
• dels anmäla sig till Bolaget senast den 22 maj 2026 per post till Scandinavian Real Heart AB, Hydrovägen 4, 721 36 Västerås, eller per e-post till jimmy.nybom@realheart.se. I anmälan ska uppges fullständigt namn, person- eller organisationsnummer, aktieinnehav, adress, telefonnummer dagtid samt, i förekommande fall, uppgift om ställföreträdare eller biträden (högst två).
För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarregistrera sina aktier, förutom att anmäla sig till stämman, låta registrera aktierna i eget namn så att aktieägaren blir upptagen i framställningen av aktieboken per avstämningsdagen den 20 maj 2026. Sådan omregistrering kan vara tillfällig (s.k. rösträttsregistrering) och begärs hos förvaltaren enligt förvaltarens rutiner i sådan tid i förväg som förvaltaren bestämmer. Rösträttsregistrering som gjorts av förvaltaren senast den 20 maj 2026 kommer att beaktas vid framställningen av bolagsstämmoaktieboken.
Ombud m.m.
Om aktieägare ska företrädas av ombud måste ombudet ha med skriftlig, daterad och av aktieägaren undertecknad fullmakt till stämman. Fullmakten får inte vara äldre än ett år om den inte anger att den är giltig under en längre tid, dock längst fem år. Om fullmakten utfärdats av juridisk person ska ombudet också ha med aktuellt registreringsbevis eller motsvarande behörighetshandling för den juridiska personen. För att underlätta inpasseringen bör kopia av fullmakt och andra behörighetshandlingar bifogas anmälan till stämman. Fullmaktsformulär hålls tillgängligt på Bolagets hemsida www.realheart.se och skickas med post till aktieägare som kontaktar Bolaget och uppger sin adress.
Behandling av personuppgifter
För information om hur personuppgifter behandlas i samband med bolagsstämman hänvisas till den integritetspolicy som finns tillgänglig på Euroclear Sweden ABs hemsida:https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.
Förslag till dagordning
1. Val av ordförande vid stämman
2. Val av en eller två justeringspersoner
3. Upprättande och godkännande av röstlängd
4. Godkännande av dagordning
5. Prövning av om stämman blivit behörigen sammankallad
6. Framläggande av årsredovisning och revisionsberättelse samt koncernredovisning och koncernrevisionsberättelse
7. Beslut
a) om fastställande av resultaträkning och balansräkning samt koncernresultaträkning och koncernbalansräkning;
b) om dispositioner beträffande Bolagets resultat enligt den fastställda balansräkningen;
c) om ansvarsfrihet åt styrelsens ledamöter och verkställande direktören
8. Fastställande av antalet styrelseledamöter och styrelsesuppleanter samt antalet revisorer och revisorssuppleanter
9. Fastställande av arvoden åt styrelsen och revisor
10. Val av styrelseledamöter och eventuella styrelsesuppleanter, styrelseordförande samt revisorer och eventuella revisorssuppleanter
11. Val av valberedning
12. Beslut om bemyndigande för styrelsen att besluta om nyemission
13. Stämmans avslutande
Valberedningens beslutsförslag
Punkt 1 – Val av ordförande vid stämman
På årsstämman 2025 valdes Claes Mellgren till valberedning. Valberedningen föreslår att Jimmy Nybom, eller den som valberedningen utser vid dennes förhinder, utses till ordförande vid årsstämman.
Punkt 8 – Fastställande av antalet styrelseledamöter och styrelsesuppleanter samt antalet revisorer och revisorssuppleanter
Valberedningen föreslår att styrelsen ska bestå av sex ordinarie styrelseledamöter utan suppleanter. Valberedningen föreslår vidare att till revisor utse ett registrerat revisionsbolag.
Punkt 9 – Fastställande av arvoden åt styrelsen och revisor
Valberedningen föreslår att arvoden till styrelsen för tiden intill slutet av nästa årsstämma ska vara oförändrat. Arvode ska utgå till styrelseordförande med 160 000 och med 77 500 kronor till var och en av de övriga ledamöter vilka ej är anställda av Bolaget.
Arvode till revisor föreslås utgå enligt godkänd räkning.
Punkt 10 – Val av styrelseledamöter och eventuella styrelsesuppleanter, styrelseordförande samt revisorer och eventuella revisorssuppleanter
Valberedningen föreslår, för tiden intill slutet av nästa årsstämma, omval av Azad Najar, Oliver Voigt, Giovanni Lauricella, Stuart McConchie, Oskar Mellgren och Mia Tomczak som styrelseledamöter. Vidare föreslås att Oskar Mellgren väljs till styrelsens ordförande.
Magnus Öhman står ej till förfogande för omval.
Till revisor föreslår valberedningen omval av det registrerade revisionsbolaget Grant Thornton Sweden AB för tiden intill årsstämman 2027. Grant Thornton Sweden AB har informerat om att den auktoriserade revisorn Joakim Söderin kommer att fortsätta som huvudansvarig revisor under förutsättning att stämman beslutar i enlighet med valberedningens förslag.
Punkt 11 – Val av valberedning
Valberedningen föreslår att årsstämman beslutar om att valberedningen inför årsstämman 2027 ska bestå av Claes Mellgren.
Styrelsens beslutsförslag
Punkt 7 b) – Beslut om dispositioner beträffande Bolagets resultat enligt den fastställda balansräkningen
Styrelsen föreslår att årsstämman beslutar att årets resultat balanseras i ny räkning och att ingen utdelning ges för räkenskapsåret 2025.
Punkt 12 – Beslut om bemyndigande för styrelsen att besluta om nyemission
Styrelsen föreslår att årsstämman beslutar om bemyndigande för styrelsen att inom ramen för gällande bolagsordning, med eller utan avvikelse från aktieägarnas företrädesrätt, vid ett eller flera tillfällen under tiden fram till nästa årsstämma, fatta beslut om ökning av Bolagets aktiekapital genom nyemission av aktier i bolaget. Syftet med bemyndigandet och skälen till eventuell avvikelse från aktieägarnas företrädesrätt är att emissioner ska kunna ske för att öka Bolagets finansiella flexibilitet och styrelsens handlingsutrymme, kunna bredda aktieägarkretsen i Bolaget samt för att kunna finansiera eventuella företagsförvärv och förvärv av verksamheter eller rörelser som Bolaget kan komma att genomföra.
Det totala antalet aktier som omfattas av sådana nyemissioner i enlighet med detta bemyndigande ska inte begränsas på annat sätt än genom gränserna för aktiekapitalet och antalet aktier såsom angivet i Bolagets vid var tid registrerade bolagsordning. Emissionerna ska ske till marknadsmässig teckningskurs, med förbehåll för marknadsmässig emissionsrabatt i förekommande fall, och betalning ska kunna ske genom kontant betalning, apportegendom eller genom kvittning, eller eljest med villkor.
Styrelsen eller den styrelsen utser bemyndigas att vidta de smärre justeringar som krävs för beslutets registrering vid Bolagsverket. För beslut i enlighet med styrelsens förslag krävs att beslutet biträds av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de aktier som är företrädda vid stämman.
Uppgifter om antalet aktier och röster
Vid tidpunkten för denna kallelses utfärdande uppgår det totala antalet aktier och röster i Bolaget till 8.497.797 stycken.
Aktieägares rätt att erhålla upplysningar
Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap. 32 § aktiebolagslagen (2005:551).
Tillhandahållande av handlingar
Bolagets årsredovisning och revisionsberättelse avseende räkenskapsåret 2025 samt övriga handlingar enligt aktiebolagslagen kommer att hållas tillgängliga för aktieägarna på Bolagets huvudkontor; Hydrovägen 4, 721 36 Västerås samt på Bolagets hemsida www.realheart.se senast tre veckor före årsstämman.
Handlingarna skickas också till de aktieägare som begär det och som uppger sin postadress.
Västerås i april 2026
Scandinavian Real Heart AB
STYRELSEN
The shareholders in Scandinavian Real Heart AB, reg. no. 556729–5588 (the "Company"), are hereby invited to the Annual General Meeting on, 28 May at 17.00 at Scandinavian Real Hearts office, Hydrovägen 4, 721 36 Västerås. Registration for the Meeting begins at 16:30.
Right to participate in the Meeting, etc.
Shareholders who wish to participate in the Meeting shall
• be recorded in the share register kept by Euroclear Sweden AB no later than 20 May 2026, and
• notify the Company their intention to participate no later than 22 May 2026 by post to Scandinavian Real Heart AB, Hydrovägen 4, 721 36 Västerås, or by e-mail to jimmy.nybom@realheart.se. The notification shall state full name, personal identification number/company registration number, shareholding, address, daytime telephone number and, if applicable, information about proxies or assistants (maximum two).
To be entitled to participate in the Meeting, shareholders whose shares are held in the name of a nominee must, in addition to providing notification of their participation in the Meeting, re-register the shares in their own name so that the shareholders are registered in the share register on the record date on 20 May 2026. This re-registration may be temporary (so-called “voting right registration”) and is carried out through the nominee according to their procedures at a time predetermined by the nominee. Voting rights registration that has been completed by the nominee no later than 20 May 2026, are considered when preparing the share register.
Proxies etc.
If a Shareholders shall be represented by proxy, the proxy shall bring a written, dated and by the shareholder signed, power of attorney to the Meeting. The power of attorney may not be older than one year unless indicated that it is valid for a longer period, not exceeding five years. If the proxy is issued by a legal person, the proxy shall bring a current copy of the registration certificate and similar papers of authorisation. In order to facilitate entry to the Meeting, a copy of the power of attorney and other authorisation documents should be attached to the notification to the Meeting. Proxy forms will be available on the Company's website www.realheart.se and will be sent by post to shareholders who contact the Company and state their address.
Processing of personal data
For information on how personal data is processed in connection with the Meeting, please refer to the privacy policy available on Euroclear Sweden AB's website: www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
Proposal for agenda
1. Election of Chairman of the Meeting
2. Election of one or two persons to verify the minutes
3. Preparation and approval of the voting list
4. Approval of the agenda
5. Determination as to whether the meeting has been duly convened
6. Presentation of the annual report and the auditor’s report and the consolidated annual report and the consolidated auditor’s report
7. Resolution on
a) adoption of the profit and loss statement and the balance sheet and the consolidated profit and loss statement and consolidated balance sheet;
b) appropriation of the Company’s profit or loss as set forth in the adopted balance sheet;
c) discharge of the Board members and the CEO from liability
8. Determination of number of Board members, deputy Board members and the number of auditors and deputy auditors
9. Determination of fees for Board members and auditor
10. Election of Board members and, where applicable, deputy Board members, Chairman of the Board and auditors and, where applicable, deputy auditors
11. Election of Nomination Committee
12. Resolution on authorisation for the Board of Directors to resolve on a new share issue
13. Closing of meeting
The Nomination Committee’s proposals
Item 1 – Election of Chairman of the Meeting
On the Annual General Meeting 2025 Claes Mellgren were elected as Nomination Committee. The Nomination Committee proposes that Jimmy Nybom, or whoever the Nomination Committee appoints in his absence, be appointed Chairman at the Annual General Meeting.
Item 8 – Determination of number of Board members, deputy Board members and the number of auditors and deputy auditors
The Nomination Committee proposes that the Board of Directors should consist of six ordinary Board members without deputies. Further, the Nomination Committee proposes to appoint a registered auditing company as auditor.
Item 9 – Determination of fees for Board members and auditor
The Nomination Committee proposes that the fees to the Board of Directors, until the end of the next Annual General Meeting, shall remain unchanged. The fees shall amount to SEK 160,000 to the Chairman of the Board of Directors and SEK 77,500 to each of the other Board members who are not employees within the Company.
Fees to the auditor are proposed to be paid according to approved invoices.
Item 10 – Election of Board members and, where applicable, deputy Board members, Chairman of the Board and auditors and, where applicable, deputy auditors
The Nomination Committee proposes, for the time until the end of the next Annual General Meeting, re-election of Azad Najar, Oliver Voigt, Giovanni Lauricella, Stuart McConchie, Oskar Mellgren and Mia Tomczak as Board members. Furthermore, it is proposed to elect Oskar Mellgren as Chairman of the Board of Directors.
Magnus Öhman is not available for re-election.
As auditor, the Nomination Committee proposes that the registered auditing firm Grant Thornton Sweden AB shall be re-elected for the period until the Annual General Meeting 2026. Grant Thornton Sweden AB has informed that, on the condition that the General Meeting decides in accordance with the Nomination Committee's proposal, the authorized public accountant Joakim Söderin will continue as auditor-in-charge.
Item 11 – Election of Nomination Committee
The Nomination Committee proposes that the Annual General Meeting resolves that the Nomination Committee for the 2027 Annual General Meeting shall consist of Claes Mellgren.
The Board of Directors’ proposals
Item 7 b – Resolution on appropriation of the Company’s profit or loss as set forth in the adopted balance sheet
The Board of Directors proposes that the Annual General Meeting shall resolve that distributable profits are carried forward and not to distribute any dividends for the financial year 2025.
Item 12 – Resolution on authorisation for the Board of Directors to resolve on a new share issue
The Board of Directors proposes that the Annual General Meeting resolve on authorisation for the Board of Directors to, within the limits of the applicable Articles of Association, with or without deviating from the shareholders' preferential rights, on one or more occasions during the period until the next Annual General Meeting, resolve on an increase in the Company's share capital through a new issue of shares in the Company. The purpose of the authorisation and the reasons for any deviation from the shareholders' preferential rights is that new issues should be able to take place in order to increase the Company's financial flexibility and the Board's capacity for action, to be able to broaden the shareholder base in the Company and to be able to finance any business mergers and acquisitions of operations or businesses that the Company may carry out.
The total number of shares to be issued by in accordance with the authorisation shall not be limited in any other way than by the limits of the share capital and the number of shares included in the Company's Articles of Association registered at any time. The issues shall be carried out at a market-based subscription price, subject to a market-based issue discount where applicable, and payment shall be made through cash payment, with property in kind or by set-off, or with other conditions.
The Board of Directors or a person appointed by the Board of Directors shall authorised to make the minor adjustments required for the registration of the resolution at the Swedish Companies Registration Office. For a valid resolution in accordance with the Board's proposal, the resolution must be supported by shareholders with at least two-thirds of both the votes cast and the shares represented at the Meeting.
Information on the number of shares and votes
At the time of issue of this notice, the total number of shares and votes in the Company amounts to 8,497,797.
Shareholders’ right to request information
The shareholders are reminded of their right, in accordance with Chapter 7 Section 32 of the Swedish Companies Act (2005:551), to request information from the Board Directors and the CEO at the Meeting.
Provision of documents
The Company's annual report and audit report for the financial year 2025 as well as other documents according to the Swedish Companies Act will be kept available to the shareholders at the Company's head office; Hydrovägen 4, 721 36 Västerås and on the Company's website www.realheart.se no later than three weeks before the Annual General Meeting. Copies of the documents will also be sent to shareholders who so request and who provide their postal address.
Västerås in April 2026
Scandinavian Real Heart AB
THE BOARD OF DIRECTORS
Västerås, Sweden, April 21, 2026 – Scandinavian Real Heart AB (publ) announces today that a new in vitro study, published in the peer-reviewed journal Artificial Organs, demonstrates that the Realheart® TAH causes approximately half the level of hemolysis – the mechanical destruction of red blood cells – compared with the only FDA-approved artificial heart device currently in wide clinical use. The differences across all primary endpoints were statistically significant (p < 0.05).
Hemolysis is a well-documented complication in patients with mechanical heart pumps. When red blood cells are damaged as they pass through a device, hemoglobin is released into the bloodstream, which over time can contribute to kidney injury, anaemia and other organ complications. Despite the clinical relevance of hemolysis, no in vitro hemolysis data for the approved device have previously been published – making this the first head-to-head laboratory comparison of two total artificial hearts using fresh human blood.
The study was conducted using human whole blood which was circulated through each device in a circulation model mimicking half of the human cardiovascular system (left side, or systemic, circulation). The results show that Realheart® TAH produced a significantly lower normalised hemolysis index (mgNIH), 18.11 ± 3.53 mg/100 L, compared with 37.15 ± 12.42 mg/100 L, than the comparator (p < 0.05). Further, plasma free hemoglobin, a direct marker of red blood cell destruction, was nearly twice as high in the comparator samples after six hours, and only the comparator significantly reduced the number of intact red blood cells relative to both the Realheart® TAH and the static control. In summary, Realheart® TAH causes significantly less harm to red blood cells than the market-approved alternative.
These results add to a growing body of experimental preclinical evidence, as well as computational modelling, indicating a favourable hemolysis profile for the Realheart® TAH design. The current study confirms that pattern in human blood, which is roughly twice as sensitive to mechanical damage as alternative experimental options (e.g. bovine blood). The tests in this study were limited to systemic circulation, and in the next step full-body circulation testing will bring the preclinical evaluation closer to the conditions the device will face in patients.
"This was our first study on human blood, and these data show that the Realheart® TAH causes significantly less blood damage than the only market-approved alternative, which is a critical biomarker evaluated by regulatory agencies. With this piece of the puzzle in place, we have moved on to more comprehensive evaluations, including full-body circulation testing, as part of our stepwise preparation for late-stage testing of our product. We have chosen to use human blood as this is more easily damaged than animal blood, which is typically used, thus giving a more clinically relevant risk assessment" says Ina Laura Perkins, CEO, Realheart.
Read the full study: http://doi.org/10.1111/aor.70149
Västerås, Sweden, April 9, 2026 – Scandinavian Real Heart AB (publ) announces today that the company’s artificial heart technology, its founder and inventor Dr. Azad Najar, and long-standing clinical research collaborator Professor Göran Dellgren are featured in the new SVT documentary series Victorias Hjärta, premiering on April 9, 2026.
Cardiovascular disease remains the leading cause of death in Sweden, and tens of millions of people globally suffer from heart failure. In the three-part documentary series, SVT science journalist and presenter Victoria Dyring shares her personal story of living with a congenital heart valve defect and the life-changing open-heart surgery that ultimately becomes unavoidable. The series provides a rare behind-the-scenes look at Swedish cardiac care, the existential realities of heart disease, and the medical advances that save lives every day.
The documentary features an interview with Dr. Azad Najar, founder and inventor of Realheart® TAH, who shares his personal journey and the motivation that drove him to dedicate over two decades to developing a better treatment for heart failure patients. Additionally, a prototype of Realheart® TAH is showcased in the documentary, illustrating the innovative four-chamber design that mimics the structure and function of the natural human heart.
Further, the series features Professor Göran Dellgren, Chief Physician at the Transplantation Center and Thorax Clinic at Sahlgrenska University Hospital in Gothenburg, and Realheart’s clinical research collaborator, as he is followed in his daily work behind the scenes. Viewers gain insight into the challenges he faces as a heart surgeon – including heart transplantation procedures – and hear him describe the role of mechanical heart pump therapy for patients with severe heart failure.
“Realheart® TAH is the only total artificial heart device in the world that mimics the structure and physiology of the natural human heart. We are very proud that our long-standing clinical collaborator Professor Dellgren’s vital work in cardiac care and our founder Azad Najar’s inspiring innovation journey are part of this important documentary. The series provides a powerful platform to raise awareness about the challenges facing heart failure patients and the urgent need for new treatment options,” says Ina Laura Perkins, CEO, Realheart.
The documentary is available for public viewing* on SVT Play from April 9, 2026.
* The documentary can only be viewed in Sweden.
Västerås, 20 mars 2026. Idag publicerar Realheart årsredovisningen för 2025.
Årsredovisningen inklusive revisionsberättelse återfinns på www.realheart.se samt som bilaga i detta pressmeddelande.
Observera att den engelska versionen, som går ut pressmeddelandet på engelska, är en översättning från det svenska originalet. Vid eventuella konflikter mellan den svenska och engelska versionen ska den svenska versionen ha företräde.
Västerås, March 20, 2026. Today, Realheart releases the annual report for 2025.
The annual report including the audit report can be found at www.realheart.se and as an attachment to this press release.
N.B. The English text is a translation of the official version in Swedish. In the event of any conflict between the Swedish and English version, the Swedish shall prevail.
Västerås, Sweden, March 4 2026 – Scandinavian Real Heart AB (publ) announces today that the company has been granted a patent approval in India. The patent covers a control method and system configuration for artificial heart products, such as Realheart® TAH, featuring integrated feedback mechanisms for real-time regulation of cardiac output. The approval grants patent protection in India until March 2041.
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The patent (IN580752) covers a control method and system configuration for an artificial heart, featuring integrated feedback mechanisms for real-time regulation of cardiac output. In detail, the system is designed to ensure precise and safe control of pump performance in medical environments.
By enabling continuous monitoring and adaptive adjustment of key parameters such as pressure, flow, and pump speed, the method supports automated control of artificial hearts and circulatory support systems, such as Realheart® TAH. This contributes to optimized hemodynamic stability and has a potential positive effect on treatment outcomes. The method and configuration are engineered for seamless integration into the company’s existing and future pump devices but can also be transferred and used in other total artificial heart suppliers’ hardware within the field of artificial hearts and circulatory support.
Country: India
Patent number: IN580752
Expiration date: March, 2041
Summary of Year-End Report H2 2025
| Group Overview | 2025-07-01 | 2024-07-01 | 2025-01-01 | 2024-01-01 | |
| 2025-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | ||
| 6 mon | 6 mon | 12 mon | 12 mon | ||
| Operating income | 62 512 | 9 674 | 153 098 | 50 054 | |
| Earnings after financial items | -16 868 193 | -20 243 850 | -35 496 149 | -34 350 238 | |
| Balance Sheet total | 72 687 887 | 83 279 673 | 72 687 887 | 83 279 673 | |
| Equity / Assets ratio | 86% | 81% | 86% | 81% | |
| Earnings per share | -3.37 | -9.79 | -7.10 | -16.61 | |
| Earnings per share after dilution | -1.99 | -2.38 | -4.18 | -4.04 | |
| Number of shares | 4 998 704 | 2 068 152 | 4 998 704 | 2 068 152 | |
| Number of shares after share issue* | 8 497 797 | 8 497 797 | 8 497 797 | 8 497 797 | |
| Parent Company Overview | 2025-07-01 | 2024-07-01 | 2025-01-01 | 2024-01-01 | |
| 2025-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | ||
| 6 mon | 6 mon | 12 mon | 12 mon | ||
| Operating income | 62 512 | 9 674 | 153 098 | 50 054 | |
| Earnings after financial items | -16 387 578 | -18 487 283 | -34 846 165 | -32 409 725 | |
| Balance Sheet total | 77 592 782 | 85 837 128 | 77 592 782 | 85 837 128 | |
| Equity / Assets ratio | 87% | 82% | 87% | 82% | |
| Earnings per share | -3.28 | -8.94 | -6.97 | -15.67 | |
| Earnings per share after dilution | -1.93 | -2.18 | -4.10 | -3.81 | |
| Number of shares | 4 998 704 | 2 068 152 | 4 998 704 | 2 068 152 | |
| Number of shares after share issue* | 8 497 797 | 8 497 797 | 8 497 797 | 8 497 797 | |
*See section about the stock on page 10 for more information.
Revenue and Result
Scandinavian Real Heart AB is currently engaged in research and development and currently has no sales of its own products. Research and development costs incurred for Realheart® TAH were capitalized during the period July 1 – December 31, 2025, in the amount of SEK 12.4 million.
Employees
The number of employees in the Group at the end of the quarter was 13 full-time employees and 2 hourly employees.
Transactions With Related Parties
No significant transactions with related parties have taken place during the period.
Significant Risks and Uncertainties
Realheart’s focus is on getting through the preclinical phase (hemolysis, GLP studies in animals and endurance tests) to be able to start clinical studies. This means that the Company must finalize the version of both the controller and the heart pump to be included in these tests. Realheart must also hold parallel discussions with the Notified Body in the EU and with the FDA in the US to ensure the fastest and safest route for the product to market. The Company is continuously working on measures to minimize delays. Furthermore, the continued product development requires that the Company can secure funding in both the short and long term. The board is continuously working on different scenarios to ensure the Company’s future operations.
Financial Position
At the end of the period, the Group’s cash and cash equivalents amounted to SEK 16.6 million. Through the Rights Issue ended January 27, 2026, the Company received approximately SEK 49 million before issue costs. At present, the Group does not generate its own positive cash flow and is thus dependent on external financing. In order to solve the longer-term financing needs, the Board of Directors is continuously evaluating options for further capitalization of the Company.
CEO Comment
The past six months have marked a productive and strategically important period for Scandinavian Real Heart, as we advanced Realheart® TAH across preclinical development while strengthening the company’s financial footing, global patent estate, and organizational alignment ahead of clinical transition.
Significant Events During the Second Half of the Year
On July 7, Realheart announces that the company has received an outstanding payment of approximately SEK 6.8 million from the European Innovation Council (EIC) following the company’s directed share issue communicated on May 2, 2025, wherein it was announced that EIC has subscribed 600,000 shares to the subscription price of SEK 11.31 per share. The European Innovation Council (EIC) has hitherto subscribed in two separate share issues resolved by the company.
On August 11, Realheart announces that the company has received its third disbursement from the European Innovation Council (EIC) grant, initially awarded in December 2021. The grant aims to support the development of the artificial heart Realheart® TAH. The payment of EUR 250,000 equals 10% of the total grant sum of EUR 2.5 million. The company was awarded a EUR 2.5 million grant within the framework of the European Innovation Council Accelerator program, aimed at supporting European innovations that have the potential to create new markets or disrupt existing ones.
On September 17, Realheart Publishes Positive Blood Flow Data Using a Groundbreaking 4D Medical Imaging Method. The company and its academic partner at Linköping University has published results from a scientific study evaluating a 3D-printed MRI-compatible artificial heart with advanced medical imaging that shows three-dimensional blood flow changes in real time (4D). The results show that Realheart® TAH produces blood flow patterns comparable to those of the natural human heart, underscoring its potential as a safe and effective treatment for severe heart disease.
On November 5, Realheart announces that the company has been granted patent approvals in China and Japan. The patents concern both the core technology of Realheart® TAH, pertaining to the structure and function of the total artificial heart, and the integrated feedback mechanism that regulates the device’s cardiac output. The recent approvals grant protection in China until 2041, and in Japan until 2041. Patent 1: patent in China covering a pressure sensor for Realheart® TAH and Patent 2: patent in Japan covering realtime regulation of Realheart® TAH.
On December 16, Realheart announces that the company resolves on a rights issue of SEK 70 million. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 70 million before issue costs. The Rights Issue is covered to approximately 70 percent by guarantee commitments and subscription commitments from existing shareholders, the Board of Directors and senior executives.
Significant Events After the End of the Period
On January 13, Realheart announces that the subscription period in the company’s rights issue starts. The company’s two main shareholders have already shown their strong commitment by announcing that they will exercise all received subscription rights under the preferential right to subscribe for new shares.
On January 14, Realheart announces that a recording of CEO Ina Laura’s company presentation, held in connection with the extraordinary general meeting on December 16, 2025, is now available. Among others, Ina Laura demonstrates today’s existing artificial heart systems and highlights their limitations from a patient perspective.
On January 28, Realheart announces outcome of the Company’s rights issue. The final outcome shows that 3,499,093 shares were subscribed for, which corresponds to approximately 70 percent of the Rights Issue. Trough the Rights Issue, the Company received approximately SEK 49 million before issue costs.
On February 11, Realheart announces that the company has been granted patent approval by the European Patent Office (EPO). The patent concerns both the core technology of Realheart® TAH, pertaining to the structure and function of the total artificial heart, and the integrated feedback mechanism that regulates the device’s cardiac output. The recent approval grants a unitary patent protecting the technology in 17 EU countries, including Realheart’s key markets, France and Germany, and its home market, Sweden, through 2041.
Västerås, Sweden, February 11, 2026 – Scandinavian Real Heart AB (publ) announces today that the company has been granted patent approval by the European Patent Office (EPO). The patent concerns both the core technology of Realheart® TAH, pertaining to the structure and function of the total artificial heart, and the integrated feedback mechanism that regulates the device’s cardiac output. The recent approval grants a unitary patent protecting the technology in 17 EU countries, including Realheart’s key markets, France and Germany, and its home market, Sweden, through 2041.
Realheart is developing Realheart® TAH, the first total artificial heart that mimics the structure and function of the native human heart. The recently approved patent covers a core technology of Realheart® TAH, producing accurate and safe pressure measurements. By enabling real-time monitoring, the patented sensor enables automated control of artificial hearts and circulatory support systems, such as Realheart® TAH. The feature is designed to provide a meaningful treatment alternative for patients awaiting a heart transplant while providing benefits that may increase the quality of life. The structural design of Realheart® TAH aims to decrease risk factors commonly associated with currently approved artificial heart treatment devices, e.g., stroke, internal bleeding, and anaemia.
Region: European Patent Office (EPO)
Patent number: 4120893
Expiration date: March 18, 2041
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, SYDAFRIKA ELLER AUSTRALIEN ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE ELLER DISTRIBUTION SKULLE VARA I STRID MED GÄLLANDE REGLER.
Scandinavian Real Heart AB (publ) (”Realheart” eller ”Bolaget”) har slutfört den företrädesemission av aktier som bolagsstämman beslutade om den 16 december 2025 (”Företrädesemissionen”). Utfallet visar att 2 502 531 aktier tecknades med stöd av teckningsrätter, motsvarande cirka 50 procent av Företrädesemissionen. Därtill har Bolaget erhållit teckningsanmälningar om 295 402 aktier, motsvarande cirka 6 procent av Företrädesemissionen, för teckning utan stöd av teckningsrätter. Totalt tecknades 2 797 933 aktier med stöd av teckningsrätter och teckningsanmälningar, motsvarande cirka 56 procent av Företrädesemissionen. Det innebär att garantiåtaganden om 701 160 aktier, motsvarande cirka 14 procent av Företrädesemissionen, kommer att utnyttjas. Totalt tecknades således 3 499 093 aktier, motsvarande cirka 70 procent av Företrädesemissionen. Genom Företrädesemissionen tillförs Bolaget cirka 49 MSEK före emissionskostnader.
Den 16 december 2025 offentliggjorde Realheart att bolagsstämman i Bolaget beslutat om en företrädesemission av aktier om cirka 70 MSEK. Teckningskursen i Företrädesemissionen var 14 SEK per aktie och det totala antalet erbjudna aktier i Företrädesemissionen uppgick till 4 998 704 stycken.
Utfallet i Företrädesemissionen
Teckningsperioden i Företrädesemissionen avslutades den 27 januari 2026. Det slutliga utfallet visar att 2 502 531 aktier tecknades med stöd av teckningsrätter, vilket motsvarar cirka 50 procent av Företrädesemissionen. Vidare har Bolaget mottagit teckningsanmälningar om att teckna 295 402 aktier utan stöd av teckningsrätter, vilket motsvarar cirka 6 procent av Företrädesemissionen. Således tecknades 2 797 933 aktier med och utan stöd av teckningsrätter, motsvarande cirka 56 procent av Företrädesemissionen. Garantiåtaganden om 701 160 aktier kommer utnyttjas av Bolaget, motsvarande cirka 14 procent av Företrädesemissionen. Sammantaget tecknades således 3 499 093 aktier.
Genom Företrädesemissionen tillförs Bolaget cirka 49 MSEK före emissionskostnader.
Tilldelning av aktier tecknade utan stöd av teckningsrätter
Tilldelning av aktier som tecknats utan stöd av teckningsrätter har skett i enlighet med de principer som anges i Informationsdokumentet som Bolaget offentliggjorde den 16 december 2025 med anledning av Företrädesemissionen. Besked om sådan tilldelning meddelas separat genom utskickad avräkningsnota. Förvaltarregistrerade aktieägare erhåller besked om tilldelning i enlighet med instruktioner från respektive förvaltare.
Aktier, aktiekapital och utspädning
Genom Företrädesemissionen ökar det totala antalet aktier i Bolaget med 3 499 093 aktier, från 4 998 704 aktier till 8 497 797 aktier, och aktiekapitalet ökar med 17 530 455 SEK, från 25 043 507 SEK till 42 573 962 SEK, motsvarande en utspädningseffekt om 41,18 procent av det totala antalet aktier och röster i Bolaget.
Handel med betalda tecknade aktier (”BTA”)
Handel med BTA sker fram till omvandling av BTA till aktier, vilket sker efter att Företrädesemissionen registrerats hos Bolagsverket. Registrering hos Bolagsverket beräknas ske under vecka 8, 2026.
Ersättning för tecknings- och garantiåtaganden
I samband med Företrädesemissionen erhöll bolaget tecknings- och garantiåtaganden. För lämnade tecknings- och garantiåtaganden utgår ingen ersättning.
Emissionsinstitut
Nordic Issuing AB är emissionsinstitut i samband med Företrädesemissionen.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
Scandinavian Real Heart AB (publ) ("Realheart" or the "Company") has completed the rights issue of shares resolved by the Extra General Meeting on 16 December 2025 (the "Rights Issue"). The outcome shows that 2,502,531 shares were subscribed for with subscription rights, corresponding to approximately 50 percent of the Rights Issue. In addition, the Company has received subscription applications for 295,402 shares, corresponding to approximately 6 percent of the Rights Issue, for subscription without subscription rights. A total of 2,797,933 shares were subscribed for with subscription rights and subscription applications, corresponding to approximately 56 percent of the Rights Issue. This means that guarantee commitments of 701,160 shares, corresponding to approximately 14 percent of the Rights Issue, will be utilized. A total of 3,499,093 shares were thus subscribed, corresponding to approximately 70 percent of the Rights Issue. Through the Rights Issue, the Company will receive approximately SEK 49 million before issue costs.
On December 16, 2025, Realheart announced that the Extra General Meeting of the Company had resolved on a rights issue of shares of approximately SEK 70 million. The subscription price in the Rights Issue was SEK 14 per share and the total number of shares offered in the Rights Issue amounted to 4,998,704.
The outcome of the Rights Issue
The subscription period in the Rights Issue ended on January 27, 2026. The final outcome shows that 2,502,531 shares were subscribed for with subscription rights, which corresponds to approximately 50 percent of the Rights Issue. Furthermore, the Company has received subscription applications to subscribe for 295,402 shares without subscription rights, which corresponds to approximately 6 percent of the Rights Issue. Thus, 2,797,933 shares were subscribed for with and without subscription rights, corresponding to approximately 56 percent of the Rights Issue. Guarantee commitments of 701,160 shares will be exercised by the Company, corresponding to approximately 14 percent of the Rights Issue. A total of 3,499,093 shares were thus subscribed.
Through the Rights Issue, the Company will receive approximately SEK 49 million before issue costs.
Allotment of shares subscribed for without subscription rights
Allotment of shares subscribed for without subscription rights has been made in accordance with the principles set out in the Information Document published by the Company on 16 December 2025 in connection with the Rights Issue. Notification of such allocation will be notified separately by means of a settlement note. Nominee-registered shareholders will receive notification of allotment in accordance with instructions from the respective nominee.
Shares, share capital and dilution
Through the Rights Issue, the total number of shares in the Company will increase by 3,499,093 shares, from 4,998,704 shares to 8,497,797 shares, and the share capital will increase by SEK 17,530,455, from SEK 25,043,507 to SEK 42,573,962, corresponding to a dilution effect of 41.18 percent of the total number of shares and votes in the Company.
Trading in paid subscribed shares ("BTA")
Trading in BTA will take place until the conversion of BTA into shares, which will take place after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place during week 8, 2026.
Compensation for subscription and guarantee commitments
In connection with the Rights Issue, the company received subscription and guarantee commitments. No compensation will be paid for subscription and guarantee commitments.
Issuing Institute
Nordic Issuing AB is the issuing agent in connection with the Rights Issue.
Scandinavian Real Heart AB (publ) announces today, January 14, 2026, that a recording of CEO Ina Laura's company presentation, held in connection with the extraordinary general meeting on December 16, 2025, is now available on the company's YouTube channel.
In the presentation, CEO Ina Laura Perkins gives an overview of the company's operations, technology platform, and strategic direction going forward. Parts of the presentation also touch on the rights issue that the company has previously communicated, the subscription period for which began yesterday, January 13, 2026. The rights issue closes on January 27.
Ina Laura also demonstrates today's existing artificial heart systems and highlights their limitations from a patient perspective. She compares these with Realheart's patient-centered solution—a heart designed to mimic the natural blood flow of the human heart and an external patient unit that is quiet, lightweight, and has a long battery life. All this is done to create the best conditions for long-term treatment of patients with severe heart failure.
As previously announced, the purpose of the issue is to finance the continued development of Realheart's artificial heart Realheart® TAH and to strengthen the company's financial position ahead of upcoming development and regulatory steps. Full terms and conditions for the issue, including the subscription period, use of issue proceeds, and other details, are set out in previous press releases.
Read more and subscribe here: https://realheart.se/preferential-rights-issue-realheart/
A recording of the presentation* is available on the Company's YouTube channel: https://youtu.be/AaaZkgmn4GM
* The presentation is in Swedish.
Scandinavian Real Heart AB (publ) meddelar idag, 14 januari 2026, att en inspelning av vd Ina Lauras bolagspresentation, som hölls i samband med den extra bolagsstämman den 16 december 2025, nu finns tillgänglig på bolagets YouTube-kanal.
I presentationen ger vd Ina Laura Perkins en övergripande presentation av bolagets verksamhet, teknologiplattform och strategiska riktning framåt. Delar av presentationen berör även den företrädesemission som bolaget tidigare har kommunicerat och vars teckningsperiod inleddes igår den 13 januari 2026. Företrädesemissionen avslutas den 27 januari.
Ina Laura demonstrerar även dagens befintliga system för artificiella hjärtan och belyser deras begränsningar ur ett patientperspektiv. Hon jämför dessa med Realhearts patientcentrerade lösning – ett hjärta som är utformat för att efterlikna det mänskliga hjärtats naturliga blodflöde och en extern patientenhet som är tyst, lätt och har lång batteritid. Allt för att skapa de bästa förutsättningarna för långsiktig behandling av svårt hjärtsviktssjuka patienter.
Som tidigare meddelats syftar emissionen till att finansiera den fortsatta utvecklingen av Realhearts artificiella hjärta Realheart® TAH samt att stärka bolagets finansiella ställning inför kommande utvecklings- och regulatoriska steg. Fullständiga villkor för emissionen, inklusive teckningsperiod, emissionslikvidens användning och övriga detaljer, framgår av tidigare pressmeddelanden.
Läs mer och teckna här: https://realheart.se/sv/foretradesemission-realheart/
Inspelningen av presentationen finns tillgänglig på Bolaget YouTube-kanal: https://youtu.be/AaaZkgmn4GM